KOL Insight: Atopic Dermatitis [2020]

Maximum Purchase:
1 unit
Publication Date:
August 2020
Licence Type:
Multi-user licence
Adding to cart… The item has been added

Therapy Trends KOL Insight: Atopic Dermatitis

What advantages do KOLs see for Eli Lilly & Co/Almirall's pipeline lebrikizumab and what are its competitive prospects against AstraZeneca/Leo Pharma's tralokinumab and Sanofi/Regeneron's established Dupixent in the first line setting? Despite their impressive efficacy, why do KOLs have concerns about JAK inhibitors such as Pfizer's abrocitinib and AbbVie's Rinvoq? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Do KOLs believe that the recent FDA approval of Sanofi/Regeneron's Dupixent for six- to 11-year-olds will expand use and solidify the product's first line position?
  • What insights do KOLs have for AstraZeneca/Leo Pharma if tralokinumab is to effectively compete with Dupixent?
  • In what settings do KOLs see potential for Incyte's topical JAK inhibitor, ruxolitinib?
  • Why are KOLs pessimistic about Galderma/Chugai/Maruho's anti-IL31 mAb nemolizumab and Vanda Pharmaceuticals' small molecule neurokinin 1 (NK1) receptor antagonist tradipitant?

Examples of Therapies Covered

Dupixent Olumiant
lebrikizumab Jakafi/Jakavi
abrocitinib Rinvoq
tradipitant nemolizumab

Partial List of Participating KOLs

  • Professor and Head of the Division of Pediatric
    Allergy National Jewish Health, Denver, CO.
  • Associate Professor of Clinical Pediatrics
    University of Southern California, Los Angeles, CA.
  • Professor of Dermatology and Pediatrics
    Feinberg School of Medicine of Northwestern University, Chicago, IL.
  • Professor of Dermatology
    Saint-Louis Hospital at the Assistance Publique Hôpitaux de Paris, Paris, France.
  • Professor of Dermatology
    University of Verona, Verona, Italy.
  • Professor of Dermatology
    Bordeaux University Hospitals, Bordeaux, France.
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Job Title*
Company Name *
Country Name *
Job Function
Account Owner